Which has stronger earnings & valuation, AGMB or IMCR?

AgomAb Therapeutics has higher earnings, but lower revenue than Immunocore. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A N/A N/A N/A Immunocore $400.02M 3.68 -$35.51M -$0.55 N/A

Does the media favor AGMB or IMCR?

In the previous week, AgomAb Therapeutics and AgomAb Therapeutics both had 2 articles in the media. AgomAb Therapeutics' average media sentiment score of 0.94 equaled Immunocore'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AgomAb Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunocore 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, ATAI or AGMB?

AgomAb Therapeutics has lower revenue, but higher earnings than Atai Beckley. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atai Beckley $4.09M 352.87 -$660.05M -$2.23 N/A AgomAb Therapeutics N/A N/A N/A N/A N/A

Does the media prefer ATAI or AGMB?

In the previous week, Atai Beckley and Atai Beckley both had 2 articles in the media. Atai Beckley's average media sentiment score of 1.00 beat AgomAb Therapeutics' score of 0.94 indicating that Atai Beckley is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atai Beckley 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AgomAb Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, GHRS or AGMB?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GH Research N/A N/A -$48.26M -$0.92 N/A AgomAb Therapeutics N/A N/A N/A N/A N/A

Is GHRS or AGMB more profitable?

AgomAb Therapeutics' return on equity of 0.00% beat GH Research's return on equity. Company Net Margins Return on Equity Return on Assets GH Research N/A -19.36% -18.73% AgomAb Therapeutics N/A N/A N/A

Which has stronger earnings & valuation, AGMB or MBX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A N/A N/A N/A MBX Biosciences N/A N/A -$86.97M -$2.21 N/A

Is AGMB or MBX more profitable?

AgomAb Therapeutics' return on equity of 0.00% beat MBX Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets AgomAb Therapeutics N/A N/A N/A MBX Biosciences N/A -24.52% -23.59%

Does the media prefer AGMB or MBX?

In the previous week, MBX Biosciences had 7 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 9 mentions for MBX Biosciences and 2 mentions for AgomAb Therapeutics. AgomAb Therapeutics' average media sentiment score of 0.94 beat MBX Biosciences' score of 0.40 indicating that AgomAb Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AgomAb Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MBX Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, AGMB or SEPN?

AgomAb Therapeutics has higher earnings, but lower revenue than Septerna. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A N/A N/A N/A Septerna $45.95M 35.27 -$48.88M -$0.81 N/A

Does the media favor AGMB or SEPN?

In the previous week, Septerna had 1 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 3 mentions for Septerna and 2 mentions for AgomAb Therapeutics. Septerna's average media sentiment score of 0.97 beat AgomAb Therapeutics' score of 0.94 indicating that Septerna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AgomAb Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Septerna 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

AgomAb Therapeutics (AGMB) Competitors

$9.61 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$9.68 +0.08 (+0.78%)

As of 06/12/2026 05:03 PM Eastern

Compare

AGMB vs. IMCR, ATAI, GHRS, MBX, and SEPN

Should you buy AgomAb Therapeutics stock or one of its competitors? MarketBeat compares AgomAb Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AgomAb Therapeutics include Immunocore (IMCR), Atai Beckley (ATAI), GH Research (GHRS), MBX Biosciences (MBX), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry.

How does AgomAb Therapeutics compare to Immunocore?

AgomAb Therapeutics (NASDAQ:AGMB) and Immunocore (NASDAQ:IMCR) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

AgomAb Therapeutics has higher earnings, but lower revenue than Immunocore.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A
Immunocore	$400.02M	3.68	-$35.51M	-$0.55	N/A

AgomAb Therapeutics presently has a consensus price target of $32.00, indicating a potential upside of 232.99%. Immunocore has a consensus price target of $56.71, indicating a potential upside of 95.84%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe AgomAb Therapeutics is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Immunocore	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

AgomAb Therapeutics has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. AgomAb Therapeutics' return on equity of 0.00% beat Immunocore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Immunocore	-6.68%	-7.07%	-2.55%

84.5% of Immunocore shares are held by institutional investors. 10.1% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, AgomAb Therapeutics and AgomAb Therapeutics both had 2 articles in the media. AgomAb Therapeutics' average media sentiment score of 0.94 equaled Immunocore'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunocore	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

AgomAb Therapeutics and Immunocore tied by winning 5 of the 10 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Atai Beckley?

Atai Beckley (NASDAQ:ATAI) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

AgomAb Therapeutics has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. AgomAb Therapeutics' return on equity of 0.00% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-19,019.44%	-89.79%	-63.58%
AgomAb Therapeutics	N/A	N/A	N/A

28.4% of Atai Beckley shares are owned by institutional investors. 26.8% of Atai Beckley shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

AgomAb Therapeutics has lower revenue, but higher earnings than Atai Beckley.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	352.87	-$660.05M	-$2.23	N/A
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A

In the previous week, Atai Beckley and Atai Beckley both had 2 articles in the media. Atai Beckley's average media sentiment score of 1.00 beat AgomAb Therapeutics' score of 0.94 indicating that Atai Beckley is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atai Beckley	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Atai Beckley currently has a consensus target price of $16.00, indicating a potential upside of 308.16%. AgomAb Therapeutics has a consensus target price of $32.00, indicating a potential upside of 232.99%. Given Atai Beckley's stronger consensus rating and higher probable upside, research analysts clearly believe Atai Beckley is more favorable than AgomAb Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Atai Beckley beats AgomAb Therapeutics on 8 of the 11 factors compared between the two stocks.

How does AgomAb Therapeutics compare to GH Research?

GH Research (NASDAQ:GHRS) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

GH Research presently has a consensus target price of $40.38, suggesting a potential upside of 91.17%. AgomAb Therapeutics has a consensus target price of $32.00, suggesting a potential upside of 232.99%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe AgomAb Therapeutics is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, AgomAb Therapeutics had 1 more articles in the media than GH Research. MarketBeat recorded 2 mentions for AgomAb Therapeutics and 1 mentions for GH Research. GH Research's average media sentiment score of 1.87 beat AgomAb Therapeutics' score of 0.94 indicating that GH Research is being referred to more favorably in the media.

Company	Overall Sentiment
GH Research	Very Positive
AgomAb Therapeutics	Positive

AgomAb Therapeutics' return on equity of 0.00% beat GH Research's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-19.36%	-18.73%
AgomAb Therapeutics	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A

56.9% of GH Research shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

AgomAb Therapeutics beats GH Research on 5 of the 8 factors compared between the two stocks.

How does AgomAb Therapeutics compare to MBX Biosciences?

AgomAb Therapeutics (NASDAQ:AGMB) and MBX Biosciences (NASDAQ:MBX) are both small-cap manufacturing companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

In the previous week, MBX Biosciences had 7 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 9 mentions for MBX Biosciences and 2 mentions for AgomAb Therapeutics. AgomAb Therapeutics' average media sentiment score of 0.94 beat MBX Biosciences' score of 0.40 indicating that AgomAb Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MBX Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

AgomAb Therapeutics presently has a consensus price target of $32.00, suggesting a potential upside of 232.99%. MBX Biosciences has a consensus price target of $60.22, suggesting a potential upside of 69.59%. Given AgomAb Therapeutics' higher possible upside, equities research analysts clearly believe AgomAb Therapeutics is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

AgomAb Therapeutics' return on equity of 0.00% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
MBX Biosciences	N/A	-24.52%	-23.59%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A

Summary

AgomAb Therapeutics and MBX Biosciences tied by winning 4 of the 8 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Septerna?

AgomAb Therapeutics (NASDAQ:AGMB) and Septerna (NASDAQ:SEPN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

AgomAb Therapeutics has a net margin of 0.00% compared to Septerna's net margin of -49.88%. AgomAb Therapeutics' return on equity of 0.00% beat Septerna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Septerna	-49.88%	-12.72%	-8.87%

AgomAb Therapeutics has higher earnings, but lower revenue than Septerna.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A
Septerna	$45.95M	35.27	-$48.88M	-$0.81	N/A

In the previous week, Septerna had 1 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 3 mentions for Septerna and 2 mentions for AgomAb Therapeutics. Septerna's average media sentiment score of 0.97 beat AgomAb Therapeutics' score of 0.94 indicating that Septerna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Septerna	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AgomAb Therapeutics currently has a consensus target price of $32.00, indicating a potential upside of 232.99%. Septerna has a consensus target price of $45.78, indicating a potential upside of 27.34%. Given AgomAb Therapeutics' higher possible upside, analysts plainly believe AgomAb Therapeutics is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Septerna	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Summary

Septerna beats AgomAb Therapeutics on 6 of the 10 factors compared between the two stocks.

Get AgomAb Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AGMB vs. The Competition

Export

Metric	AgomAb Therapeutics	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$348.24M	$407.67M	$4.29B	$12.05B
Dividend Yield	N/A	N/A	10.25%	5.66%
P/E Ratio	N/A	N/A	22.29	24.42
Price / Sales	N/A	320.73	159.54	111.24
Price / Cash	N/A	N/A	40.19	37.92
Price / Book	N/A	2.49	26.92	6.82
Net Income	N/A	-$81.71M	$116.61M	$337.56M
7 Day Performance	-6.79%	-0.93%	0.25%	1.17%
1 Month Performance	-8.91%	-12.31%	0.25%	3.16%
1 Year Performance	N/A	N/A	14.25%	30.58%

AgomAb Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AGMB AgomAb Therapeutics	N/A	$9.61 flat	$32.00 +233.0%	N/A	$348.24M	N/A	N/A	62	Gap Up
IMCR Immunocore	3.0832 of 5 stars	$28.52 +2.6%	$56.71 +98.9%	-16.5%	$1.41B	$400.02M	N/A	320
ATAI Atai Beckley	3.9777 of 5 stars	$3.89 +2.1%	$16.00 +311.3%	+85.8%	$1.40B	$4.09M	N/A	80	Positive News
GHRS GH Research	3.1229 of 5 stars	$20.35 +1.1%	$40.38 +98.4%	+65.5%	$1.38B	N/A	N/A	10	Positive News
MBX MBX Biosciences	2.6747 of 5 stars	$29.87 +3.0%	$60.22 +101.6%	N/A	$1.38B	N/A	N/A	N/A	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AGMB) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AgomAb Therapeutics (AGMB) Competitors

AGMB vs. IMCR, ATAI, GHRS, MBX, and SEPN

How does AgomAb Therapeutics compare to Immunocore?

Summary

How does AgomAb Therapeutics compare to Atai Beckley?

Summary

How does AgomAb Therapeutics compare to GH Research?

Summary

How does AgomAb Therapeutics compare to MBX Biosciences?

Summary

How does AgomAb Therapeutics compare to Septerna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGMB vs. The Competition

AgomAb Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AgomAb Therapeutics (AGMB) Competitors

AGMB vs. IMCR, ATAI, GHRS, MBX, and SEPN

How does AgomAb Therapeutics compare to Immunocore?

Which has stronger earnings & valuation, AGMB or IMCR?

Do analysts prefer AGMB or IMCR?

Is AGMB or IMCR more profitable?

Do institutionals & insiders believe in AGMB or IMCR?

Does the media favor AGMB or IMCR?

Summary

How does AgomAb Therapeutics compare to Atai Beckley?

Is ATAI or AGMB more profitable?

Do institutionals and insiders hold more shares of ATAI or AGMB?

Which has stronger valuation & earnings, ATAI or AGMB?

Does the media prefer ATAI or AGMB?

Do analysts rate ATAI or AGMB?

Summary

How does AgomAb Therapeutics compare to GH Research?

Do analysts rate GHRS or AGMB?

Does the media prefer GHRS or AGMB?

Is GHRS or AGMB more profitable?

Which has higher valuation & earnings, GHRS or AGMB?

Do institutionals & insiders have more ownership in GHRS or AGMB?

Summary

How does AgomAb Therapeutics compare to MBX Biosciences?

Does the media prefer AGMB or MBX?

Do analysts prefer AGMB or MBX?

Is AGMB or MBX more profitable?

Which has stronger earnings & valuation, AGMB or MBX?

Summary

How does AgomAb Therapeutics compare to Septerna?

Is AGMB or SEPN more profitable?

Which has higher earnings and valuation, AGMB or SEPN?

Does the media favor AGMB or SEPN?

Do analysts rate AGMB or SEPN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGMB vs. The Competition

AgomAb Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools